Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565775 | 1.00 | TAAR1 (0.45) | TAAR1GAAABCB11PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL29401350 | 0.98 | TAAR1 (0.44) | TAAR1GAAABCB11PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL840329 | 0.98 | TAAR1 (0.44) | TAAR1GAAABCB11PTGS1PTGS2 | |
| SCHEMBL1144086 | 0.83 | GAA (0.44) | TAAR1GAALMNAALDH1A1MAPT | |
| SCHEMBL359674 | 0.83 | ALDH1A1 (0.41) | TAAR1GAAPTGS2LMNAALDH1A1 | |
| Bromide SCHEMBL20984793 | 0.80 | GAA (0.42) | TAAR1GAALMNAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1805607 | 0.80 | ALDH1A1 (0.39) | TAAR1GAAPTGS2LMNAALDH1A1 | |
| Bromide SCHEMBL20984375 | 0.80 | ALDH1A1 (0.39) | TAAR1GAAPTGS2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL839849 | 0.80 | GAA (0.42) | TAAR1GAALMNAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL21357474 | 0.78 | GAA (0.41) | TAAR1GAALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845786-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240261292-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2024-08-08 | — | — | US | disclosed |
| WO-2024114664-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114666-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4337215-A1 | COMBINATION THERAPIES | JANSSEN Pharmaceutica NV (BE) | 2024-03-20 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | TAAR1 1307/4885GAA 3654/4885ABCB11 4084/4885 |
| US-20240261292-A1 | COMBINATION THERAPIES | IDH3B, DHODH, IDH3A | TAAR1 4148/4885GAA 4189/4885ABCB11 3978/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | TAAR1 4400/4885GAA 4660/4885ABCB11 3428/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | TAAR1 1307/4885GAA 3654/4885ABCB11 4084/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | TAAR1 1307/4885GAA 3654/4885ABCB11 4084/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | TAAR1 2984/4885GAA 2028/4885ABCB11 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.